Clinical profile and outcome of large-vessel giant cell arteritis in Japanese patients: A single-centre retrospective cohort study

被引:8
|
作者
Yamaguchi, Eriho [1 ]
Kadoba, Keiichiro [1 ]
Watanabe, Ryu [2 ]
Iwasaki, Takeshi [1 ,3 ]
Kitagori, Koji [1 ]
Akizuki, Shuji [1 ]
Murakami, Kosaku [1 ]
Nakashima, Ran [1 ]
Hashimoto, Motomu [2 ]
Tanaka, Masao [2 ]
Morinobu, Akio [1 ]
Yoshifuji, Hajime [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Rheumatol & Clin Immunol, Kyoto, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Adv Med Rheumat Dis, Kyoto, Japan
[3] Kyoto Univ, Ctr Genom Med, Grad Sch Med, Kyoto, Japan
基金
日本学术振兴会;
关键词
Diagnostic imaging; giant cell arteritis; large vessel involvement; ophthalmic manifestations; TAKAYASU ARTERITIS; INITIAL VALIDATION; ACTIVITY SCORE; VASCULITIS; DAMAGE; INVOLVEMENT; ANEURYSM; IL12B; HLA;
D O I
10.1093/mr/roac013
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Recent advances in imaging revealed that giant cell arteritis (GCA) is frequently associated with large vessel involvement (LVI), but they may also contribute to earlier diagnosis and treatment of LV-GCA. We aimed to compare the clinical characteristics of GCA with or without LVI and evaluate its association with clinical outcomes. Method We retrospectively reviewed the medical records of 36 patients with GCA in Kyoto University Hospital. Results Eighteen patients each were assigned to the LVI(+) and LVI(-) groups. Five-year survival rates in the LVI(+) group were better than in the LVI(-) group (p = .034), while five-year relapse-free survival rates were similar between the groups (p = .75). The LVI(+) group required lower doses of glucocorticoid at month 6 (p = .036). Disease activity evaluated with the Birmingham Vasculitis Activity Score at disease onset was higher in the LVI(-) group (p = .014), and the Vasculitis Damage Index score examined at the last visit was higher in the LVI(-) group (p = .011). Conclusion GCA without LVI had more active disease, severer vascular damage, and worse survival, possibly because of ophthalmic complications and their greater glucocorticoid requirement. Our results revisit the impact of cranial manifestations on disease severity and morbidity.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 50 条
  • [41] Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
    de Boysson, Hubert
    Liozon, Eric
    Espitia, Olivier
    Daumas, Aurelie
    Vautier, Mathieu
    Lambert, Marc
    Parienti, Jean-Jacques
    Manrique, Alain
    Saadoun, David
    Ly, Kim Heang
    Agard, Christian
    Aouba, Achille
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [42] Different patterns and specific outcomes of large-vessel involvements in giant cell arteritis
    de Boysson, Hubert
    Liozon, Eric
    Espitia, Olivier
    Daumas, Aurelie
    Vautier, Mathieu
    Lambert, Marc
    Parienti, Jean-Jacques
    Granel, Brigitte
    Dumont, Anael
    Sultan, Audrey
    Manrique, Alain
    Saadoun, David
    Ly, Kim Heang
    Agard, Christian
    Aouba, Achille
    JOURNAL OF AUTOIMMUNITY, 2019, 103
  • [43] Large-vessel giant cell arteritis after COVID-19 vaccine
    Mejren, A.
    Sorensen, C. M.
    Gormsen, L. C.
    Tougaard, R. S.
    Nielsen, B. D.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2022, 51 (02) : 154 - 155
  • [44] Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study
    Mensch, Noemi
    Hemmig, Andrea Katharina
    Aschwanden, Markus
    Imfeld, Stephan
    Stegert, Mihaela
    Recher, Mike
    Staub, Daniel
    Kyburz, Diego
    Berger, Christoph T.
    Daikeler, Thomas
    RMD OPEN, 2023, 9 (03):
  • [45] Risk factors for symptomatic vascular events in giant cell arteritis: a study of 254 patients with large-vessel imaging at diagnosis
    de Mornac, Donatienne
    Agard, Christian
    Hardouin, Jean-Benoit
    Hamidou, Mohamed
    Connault, Jerome
    Masseau, Agathe
    Espitia-Thibault, Alexandra
    Artifoni, Mathieu
    Ngohou, Chan
    Perrin, Francois
    Graveleau, Julie
    Durant, Cecile
    Pottier, Pierre
    Neel, Antoine
    Espitia, Olivier
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [46] Clinical Manifestations and Prognosis of Giant Cell Arteritis: A Retrospective Cohort Study
    Fedorinova, E. E.
    Bulanov, N. M.
    Meshkov, A. D.
    Borodin, O. O.
    Smitienko, I. O.
    Chachilo, E. V.
    Nartov, A. A.
    Filatova, A. L.
    Naumov, A. V.
    Novikov, P. I.
    Moiseev, S. V.
    DOKLADY BIOCHEMISTRY AND BIOPHYSICS, 2024, 517 (01) : 250 - 258
  • [47] COULD THE RENIN-ANGIOTENSIN SYSTEM AFFECT THE PROGNOSIS OF GIANT CELL ARTERITIS? SINGLE-CENTRE RETROSPECTIVE OBSERVATIONAL STUDY
    Venkateswaran, R.
    Gour, K.
    Sorensen, L.
    Harden, C.
    Zhao, S. S.
    Morgan, A.
    Mackie, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1204 - 1205
  • [48] EFFICACY OF TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS: A SINGLE-CENTER REAL-LIFE EXPERIENCE
    Tomelleri, A.
    Campochiaro, C.
    Sartorelli, S.
    Baldissera, E.
    Dagna, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1559 - 1560
  • [49] HLA-B52 allele in giant cell arteritis may indicate diffuse large-vessel vasculitis formation: a retrospective study
    Kushimoto, Kazuo
    Ayano, Masahiro
    Nishimura, Keisuke
    Nakano, Miki
    Kimoto, Yasutaka
    Mitoma, Hiroki
    Ono, Nobuyuki
    Arinobu, Yojiro
    Akashi, Koichi
    Horiuchi, Takahiko
    Niiro, Hiroaki
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [50] Large-vessel giant cell arteritis eleven months after a diagnosis of erythema nodosum
    Tsuji, Takahiro
    Kunitomo, Kotaro
    MODERN RHEUMATOLOGY CASE REPORTS, 2020, 4 (02) : 283 - 288